<DOC>
	<DOCNO>NCT00157521</DOCNO>
	<brief_summary>Pre-eclampsia disorder unique pregnancy affect mother fetus . Hypertension , proteinuria edema common well-known maternal clinical symptom . The incidence approximately 6-8 % . Pre-eclampsia one leading cause maternal fetal mortality morbidity associate pregnancy throughout world . The pathophysiology unknown . At present , effective treatment immediate delivery . The researcher ' study contribute demonstration vasodilator nitric oxide ( NO ) important correct placentation less nitric oxide ( NO ) - dependent vasodilation excess formation reactive oxygen specie explain poor placenta perfusion pre-eclampsia . This reduced NO activity increase oxidative stress pre-eclamptic placenta relate low bioavailability L-arginine , NO precursor . In pilot study researcher want evaluate whether administration L-arginine woman clinical diagnosis preeclampsia might restore physiological NO production placenta ameliorate pregnancy outcome .</brief_summary>
	<brief_title>L-Arginine Pre-Eclampsia</brief_title>
	<detailed_description>INTRODUCTION In past year evidence accumulate strongly suggest nitric oxide ( NO ) , potent endothelial-derived vasodilator , might implicate gestational vasodilatation . NO synthesized aminoacid L-arginine family enzyme , NO synthases ( NOS ) . The endothelial isoform nitric oxide synthase ( ecNOS ) find human placenta immunohistochemically localized endothelium umbilical cord , chorionic plate stem villous vessel . Locally form ecNOS-dependent NO may serve maintain low vascular resistance besides attenuate action vasoconstrictor . With unique angiogenic/vasculogenic property , NO instrumental promote cytotrophoblast endovascular invasion uterine spiral artery , essential feature normal placentation . Inadequate production vasodilator nitric oxide ( NO ) placenta recently suggest explain high resistance state ineffective placentation pre-eclampsia , however result date conflicting . We recently find placental endothelial NO synthase ( ecNOS ) expression activity comparable normal pregnancy pre-eclampsia , pre-eclamptic placenta NO degrade peroxynitrite , good candidate mediate oxidative damage pre-eclampsia . Concentration NO precursor L-arginine low pre-eclampsia , suggest defect L-arginine bioavailability placenta . These result provide biochemical explanation defective NO synthesis pre-eclamptic placenta since NO production endothelial NO synthase ( ecNOS ) strongly dependent availability substrate L-arginine low L-arginine availability induces NOS synthesize peroxynitrite expense NO . These result suggest , normal placenta , adequate concentration L-arginine selectively orient ecNOS toward NO , vital normal placentation.In pre-eclamptic placenta , instead , low normal L-arginine concentration re-directs ecNOS toward peroxynitrite generate exuberant amount expense NO . This favor microvascular damage impairs cytotrophoblast invasion . Thus , whether increase L-arginine bioavailability might restore physiological NO production pre-eclamptic placenta worth investigate pilot study might represent basis large , multicenter trial aim explore impact treatment pregnancy outcome . AIMS Primary - To compare L-arginine NO metabolite ( NO2-/NO3- ) concentration systemic umbilical cord blood , placental ecNOS , nitrotyrosine HNE-lysine staining level conjugate dienes ten pre-eclamptic woman give L-Arginine supplementation ten pre-eclamptic woman give placebo . - To compare L-arginine transport activity normal pre-eclamptic placenta syncytiotrophoblasts vitro . To compare mRNA expression cationic aminoacid system ( Y+ LAT , CAT-2 CAT-4 ) normal pre-eclamptic placenta . Secondary - To compare pre-eclamptic woman give L-Arginine supplementation pre-eclamptic woman give placebo follow : - Time pre-eclampsia onset delivery - Arterial blood pressure , albuminuria , proteinuria , complete blood cell count include platelet count , serum creatinine , uric acid , triglyceride , cholesterol , C3 , GOT , GPT , GammaGT , HDL , LDL LDH concentration time delivery - Structural change placenta - Newborn weight , height , Apgar score - Gestational age delivery DESIGN Ten woman clinical diagnosis pre-eclampsia give oral L-arginine supplementation time diagnosis ( case ) ten woman clinical diagnosis pre-eclampsia placebo ( control ) match case age , parity , time onset pre-eclampsia concomitant risk factor ( chronic hypertension , diabetes , renal disease , multiple pregnancy ) select study participation . Cases control also receive conventional therapy ( antihypertensive drug : nifedipine , alpha-methyldopa ; magnesium prophylaxis eclampsia ; betamethasone fetus maturation ) pre-eclampsia homogenous treatment . Ten normotensive pregnant woman ( normotensive pregnancy ) match gestational age type delivery ( cesarean vaginal ) also study . All subject provide write informed consent accord declaration Helsinki . Patients enter study soon diagnosis pre-eclampsia do .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<criteria>1 . Preeclamptic woman Pregnancy – induce hypertension ( diastolic blood pressure [ DBP ] ≥ 90 mm Hg ) Proteinuria ≥ 300 mg/24 h albuminuria ≥ 250 µg/min and/or Early sign intrauterine growth restriction ( IUGR ) 2 standard deviation mean gestational age patient previous ultrasound test 20th week gestation 2 . Normotensive pregnant woman Diastolic blood pressure &lt; 90 mm Hg No history hypertension No significant proteinuria No sign infection No sign IUGR Matched gestational age preeclamptic woman History hypersensitivity larginine Legal incapacity and/or circumstance render patient unable understand nature , scope possible consequence trial Evidence uncooperative attitude Any evidence allows predict patient able complete trial followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>